Results 131 to 140 of about 150,460 (322)
Movement Disorders Clinical Practice, EarlyView.Abstract Background Impulse control disorders (ICD) are common non‐motor complications in Parkinson's disease (PD), particularly in patients receiving oral dopamine agonists (DA). Continuous subcutaneous apomorphine infusion (CSAI) is a device‐aided therapy for advanced PD, but its effects on ICD remain underexplored in real‐world settings.
Clément Desjardins +249 more
wiley +1 more source
D₂ Dopamine Receptors Colocalize Regulator of G-Protein Signaling 9-2 (RGS9-2) via the RGS9 DEP Domain, and RGS9 Knock-Out Mice Develop Dyskinesias Associated with Dopamine Pathways [PDF]
, 2005 Regulator of G-protein signaling 9-2 (RGS9-2), a member of the RGS family of Gα GTPase accelerating proteins, is expressed specifically in the striatum, which participates in antipsychotic-induced tardive dyskinesia and in levodopa-induced dyskinesia. We
Axelrod, Jeffrey D. +10 more
core
Cholinergic System Changes in Dopa‐Unresponsive Freezing of Gait in Parkinson's Disease
Movement Disorders, EarlyView.Abstract Background Freezing of gait (FoG) is a debilitating mobility disturbance that becomes increasingly resistant to dopaminergic pharmacotherapies with advancing Parkinson's disease (PD). The pathophysiology underlying the response of FoG to dopaminergic treatment is poorly understood.
Kelvin L. Chou +6 more
wiley +1 more source
Basic and Clinical Neuroscience, 2015 Introduction: The hippocampus (HIP), the primary brain structure related to learning and memory, receives sparse but comprehensive dopamine innervations and contains dopamine D1/D2-like receptors.
Behrooz Khakpour-Taleghani +2 more
doaj
Movement Disorders, EarlyView.Abstract Background Individual variability in clinical response to dopamine replacement therapy (DRT) is a key barrier to efficacious treatment for patients with Parkinson's disease (PD). A better understanding of the neurobiological sources of such interindividual differences is necessary to personalize DRT prescribing, inform future clinical ...
Alex I. Wiesman +5 more
wiley +1 more source
Movement Disorders, EarlyView.ABSTRACT Neuroimaging with positron emission tomography (PET) has been instrumental in elucidating neurobiological mechanisms behind therapeutical trials in Parkinson's disease (PD). A variety of medical and neurosurgical interventions have been evaluated using many radioligands that reveal molecular basis for target engagement and brain responses in ...
Vijay Dhawan +4 more
wiley +1 more source
PAIN Reports. Introduction:. The lateral parabrachial nucleus (LPBN), a crucial hub for integrating and modulating diverse sensory information, is known to express both D1 and D2 dopamine receptors and receive dopaminergic inputs.
Ho Koo +4 more
doaj +1 more source
Dopamine and glucose, obesity and Reward Deficiency Syndrome
Frontiers in Psychology, 2014 Obesity and many well described eating disorders are accurately considered a global epidemic. The consequences of Reward Deficiency Syndrome, a genetic and epigenetic phenomena that involves the interactions of powerful neurotransmitters, are impairments
Kenneth eBlum +2 more
doaj +1 more source
Movement Disorders, EarlyView.Abstract Traditionally, clinical trials of putative disease‐modifying therapies in Parkinson's disease have enrolled untreated patients at the earliest clinical stages of their disease. Due to a number of challenges inherent with this approach, there has been a recent move to a different study design, enrolling patients who are already taking “stable ...
M. Maral Mouradian +2 more
wiley +1 more source
Brain Research Bulletin, 2022 Beta band (12–30 Hz) hypersynchrony within the basal ganglia-thalamocortical network has been suggested as a hallmark of Parkinson’s disease (PD) pathophysiology. Abnormal beta band oscillations are found in the pedunculopontine nucleus (PPN) and primary
Xuenan Wang +7 more
doaj